


National Biopharma Mission completes 5 years, launches impact book

09 August 2024 | News

"National Biopharma Mission (NBM) achieved a milestone by launching 18 successful products and 200 grantees in Vaccines, Biotherapeutics & Medical Devices and Diagnostics": Dr Singh



"Bio-Economy and Space Economy are going to spearhead India's future growth story" says Union Minister Dr Jitendra Singh at the launch of 'Impact Report 2024' on National Biopharma Mission at the National Biopharma Mission Conclave celebrating its 5 years journey at the Dr. Ambedkar International Centre, New Delhi.

Union Minister of State (Independent Charge) for Science and Technology, Dr Jitendra Singh recalled the journey of National Biopharma Mission since its inception along with Biotechnology Industry Research Assistance Council (BIRAC) "National Biopharma Mission (NBM) is Celebrating 5 Years of Pioneering Success" and called it a milestone.

The National Biopharma Mission (NBM)- Innovate in India (I3) is an Industry-Academia Collaborative Mission for Accelerating Discovery Research for development of Biopharmaceuticals. BIRAC has the mandate to enable and nurture an ecosystem for preparing India's technological and product development capabilities in bio pharmaceuticals, vaccines, biosimilars, medical devices and diagnostics. The project was sanctioned with a total cost \$250 million which is 50% co-funded by the World Bank. Today nearly 150 organisations and 300 MSMEs are being benefited from the programme.

NBM has established 21 shared infrastructure facilities for research services and biomanufacturing. These facilities were also leveraged for the COVID-19 vaccine trials during the pandemic and are an important step towards India @2047, saving both cost & time. National Biopharma Mission has supported more than 200 grantees in three main domains: Vaccines,

Biotherapeutics & Medical Devices and Diagnostics while also strengthening the ecosystem. The Mission has introduced over 18 successful products to the market including vaccines, biotherapeutics, medical devices, and diagnostic kits.